Context Therapeutics
CNTX0.58476.04% ( -0.0376 )
Context Therapeutics (CNTX)
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate incl...
- Open
- 0.6200
- High
- 0.6200
- Low
- 0.5720
- Prev. Close
- 0.6223
- Volume
- 1.35M
- Turnover
- 790.38K
- Avg Price
- 0.5859
- Bid/Ask Ratio
- --
- Amplitude
- 7.71%
- 52wk High
- 3.6200
- Volume Ratio
- 1.81
- Turnover Ratio
- 3.03%
Context Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 22, 2026Price forecast
$5.38819.27%
Forecast & RatingStrong buy
10analysts
- Strong buy70.00%
- Buy30.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 12 at 09:40 PM
Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Growth in Short Interest
- Unusual Whales · Jul 10 at 03:22 PM
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- PUBT · Jul 10 at 03:05 PM
Context Therapeutics grants new hire stock options for 146,000 shares at $0.7 each
- StockTitan · Jul 6 at 07:07 AM
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes | CNTX Stock News
- PUBT · Jun 26 at 03:08 PM
Context Therapeutics shareholders approve increase in authorized common shares to 300 million
- Tip Ranks · Jun 15 at 12:55 PM
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
